Advertisement


Matthew J. Ellis, PhD, FRCP: Update on Translational Research

2015 San Antonio Breast Cancer Symposium

Advertisement

Matthew J. Ellis, PhD, FRCP, of the Baylor College of Medicine, gives his expert perspective on this evolving area of research.



Related Videos

Breast Cancer

Sherene Loi, MD, on Triple-Negative Breast Cancer: A Pooled Data Analysis

Sherene Loi, MD, of Peter MacCallum Cancer Centre, discusses a pooled individual patient data analysis of stromal tumor-infiltrating lymphocytes in primary triple-negative breast cancer treated with anthracycline-based chemotherapy (Abstract S1-03).

Breast Cancer

Andrew Seidman, MD, and Norman Wolmark, MD, on NSABP Clinical Trials and Management of Early Breast Cancer

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Norman Wolmark, MD, of Allegheny General Hospital, discuss the landmark trials of NSABP that have led to profound changes in breast cancer treatment. (Abstract ML-1)

Breast Cancer

Andrew Seidman, MD, and Ruth O'Regan, MD: Update on Early Breast Cancer

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Ruth M. O’Regan, MD, of the University of Wisconsin, review practice-changing research in 2015 that was focused on early-stage breast cancer.

Breast Cancer

Jame Abraham, MD, on The JAVELIN and KEYNOTE-028 Study Results

Jame Abraham, MD, of the Cleveland Clinic, discusses findings on the use of avelumab, an anti–PD-L1 antibody, in patients with locally advanced or metastatic breast cancer, as well as the preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor–positive/HER2-negative disease (Abstracts S1-04, S5-07).

Breast Cancer

Andrew Seidman, MD, and Hope Rugo, MD, on Advanced Breast Cancer: KEYNOTE-028 Study Results

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor-positive/HER2-negative disease. (Abstract S5-07)

Advertisement

Advertisement



Advertisement